Deep Learning in Therapeutic Antibody Development.

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Artificial Intelligence in Drug Discovery

Background:

• Deep learning for antibody development is nascent, facing challenges from limited data and platform variability.
• Existing models for general protein behavior and early antibody prediction indicate future potential due to shared antibody structures.

Purpose of the Study:

• To explore the potential of deep learning in advancing antibody development.
• To address the challenges of low data volumes and platform differences in supervised antibody modeling.

Main Methods:

• Leveraging successes in general protein modeling and early antibody models.
• Utilizing new data collection techniques and unsupervised/self-supervised deep learning methods (e.g., generative and masked language models).

Main Results:

• New deep learning methods offer the potential for richer datasets and advanced architectures.
• These advancements pave the way for more robust supervised models for antibody development.

Conclusions:

• The integration of advanced deep learning techniques is crucial for overcoming current limitations in antibody development.
• These innovations are expected to enhance biotherapeutic developability, lower production costs, and broaden access to medicines.